Login to Your Account



Other News To Note


Wednesday, November 2, 2011

• Activartis Biotech GmbH, of Vienna, Austria, said it expects interim results from an ongoing Austrian Phase II trial of its cancer vaccine in glioblastoma multiforme in the second half of next year. Activartis' technology uses autologous dendritic cells to activate tumor-specific T cells and activates release of interleukin 12, a signaling molecule key to polarizing an immune response based on killer T-cell activity. The primary objective of the randomized, open-label, two-arm trial is progression-free survival, with overall survival as the secondary goal.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription